Overview

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

Status:
RECRUITING
Trial end date:
2030-04-30
Target enrollment:
Participant gender:
Summary
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Phase:
PHASE1
Details
Lead Sponsor:
Daiichi Sankyo
Collaborator:
Merck Sharp & Dohme LLC
Treatments:
pembrolizumab